Bristol Myers Squibb Joins Jiangsu Hengrui in $15.2B Collaboration on 13 Programs
BMY•Bristol Myers Squibb struck a collaboration with Jiangsu Hengrui to develop 13 early-stage oncology, hematology & immunology programs and potential $15.2 billion in milestones. The stock trades at 9× forward earnings versus a 16.8× sector average and yields 4.5%, though patent cliffs for Opdivo and Eliquis could pressure near-term revenue.
1. Strategic Collaboration Details
Bristol Myers Squibb and Jiangsu Hengrui agreed to co-develop 13 early-stage programs spanning oncology, hematology and immunology, pooling discovery and development resources to accelerate innovation. The partnership aims to leverage Hengrui’s discovery capabilities with Bristol Myers Squibb’s development expertise to expand its pipeline footprint in high-growth therapeutic areas.
2. Financial Terms and Pipeline Impact
The agreement carries up to $15.2 billion in potential milestone payments tied to clinical and commercial milestones across the joint programs. Successful advancement of these assets could drive long-term revenue growth and diversify Bristol Myers Squibb’s portfolio beyond its established biologics.
3. Valuation and Patent Risks
Shares trade at roughly 9× forward earnings, well below the healthcare sector average of 16.8×, and return a 4.5% dividend yield, reflecting a value proposition amid growth concerns. However, impending patent expirations for blockbusters Opdivo and Eliquis could weigh on near-term sales absent offsetting launches from the new collaboration.
